Skip to content

Study · Randomized controlled trial · n = 34 · 2018

3 results

Pasireotide does not improve efficacy of aspiration sclerotherapy in patients with large hepatic cysts, a randomized controlled trial.

Wijnands TFM, Gevers TJG, Lantinga MA, Te Morsche RH, Schultze Kool LJ, Drenth JPH

European radiology9 Jan 2018Cited by 14 (Europe PMC)

PMID29318424 (opens in a new tab)PMCIDPMC5938297 (opens in a new tab)DOI10.1007/s00330-017-5205-1 (opens in a new tab)PepBankPUB-29318424
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

ObjectivesWe tested whether complementary use of the somatostatin analogue pasireotide would augment efficacy of aspiration sclerotherapy of hepatic cysts.MethodsWe conducted a double-blind, placebo-controlled trial in patients who underwent aspiration sclerotherapy of a large (>5 cm) symptomatic hepatic cyst. Patients were randomized to either intramuscular injections of pasireotide 60 mg long-acting release (n = 17) or placebo (sodium chloride 0.9 %, n = 17). Injections were administered 2 weeks before and 2 weeks after aspiration sclerotherapy. The primary endpoint was proportional cyst diameter reduction (%) from baseline to 6 weeks. Secondary outcomes included long-term cyst reduction at 26 weeks, patient-reported outcomes including the polycystic liver disease-questionnaire (PLD-Q) and safety.ResultsThirty-four patients (32 females; 53.6 ± 7.8 years) were randomized between pasireotide or placebo. Pasireotide did not improve efficacy of aspiration sclerotherapy at 6 weeks compared to controls (23.6 % [IQR 12.6-30.0] vs. 21.8 % [9.6-31.8]; p = 0.96). Long-term cyst diameter reduction was similar in both groups (49.1 % [27.0-73.6] and 45.6 % [29.6-59.6]; p = 0.90). Mean PLD-Q scores improved significantly in both groups (p < 0.01) without differences between arms (p = 0.92).ConclusionsIn patients with large symptomatic hepatic cysts, complementary pasireotide to aspiration sclerotherapy did not improve cyst reduction or clinical response.Key points• Complementary pasireotide treatment does not improve efficacy of aspiration sclerotherapy. • Cyst fluid reaccumulation after aspiration sclerotherapy is a transient phenomenon. • Aspiration sclerotherapy strongly reduces symptoms and normalizes quality of life.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In hepatic cyst patients receiving sclerotherapy, cyst diameter reduction at 6 weeks was 23.6% (IQR 12.6-30.0) with pasireotide versus 21.8% (9.6-31.8) with placebo, without significant difference (p=0.96).

    In plain wordsIn hepatic cyst patients receiving sclerotherapy, cyst reduction at six weeks was similar with pasireotide and placebo.

    Peptide
    Pasireotide
    Outcome
    No significant changeCyst diameter reduction at 6 weeks
    Study

    n = 34

    Comparator
    Placebo with aspiration sclerotherapy
    Analysis
    Primary
    Outcome group
    Cyst size · Liver
    Studied dose
    60 mg long-acting release, two injections · intramuscular · Injections 2 weeks before and 2 weeks after aspiration sclerotherapyAs given in this study (human).

    Measurements

    Proportional cyst diameter reduction at 6 weeks
    23.6%
    pasireotide LAR
    Proportional cyst diameter reduction at 6 weeks
    21.8%
    placebo
    IQR, cyst diameter reduction at 6 weeks
    12.6 to 30%
    pasireotide LAR
    IQR, cyst diameter reduction at 6 weeks
    9.6 to 31.8%
    placebo
    P value
    0.96
    pasireotide versus placebo, 6 weeks

    Source sentences

    Summary
    Pasireotide did not improve efficacy of aspiration sclerotherapy at 6 weeks compared to controls (23.6 % [IQR 12.6-30.0] vs. 21.8 % [9.6-31.8]; p = 0.96).
    3 context sentences
    Summary · context
    We conducted a double-blind, placebo-controlled trial in patients who underwent aspiration sclerotherapy of a large (>5 cm) symptomatic hepatic cyst.
    Summary · context
    Patients were randomized to either intramuscular injections of pasireotide 60 mg long-acting release (n = 17) or placebo (sodium chloride 0.9 %, n = 17).
    Summary · context
    Injections were administered 2 weeks before and 2 weeks after aspiration sclerotherapy.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In hepatic cyst patients receiving sclerotherapy, cyst diameter reduction at 26 weeks was 49.1% (IQR 27.0-73.6) with pasireotide versus 45.6% (29.6-59.6) with placebo, without significant difference (p=0.90).

    In plain wordsIn hepatic cyst patients receiving sclerotherapy, long-term cyst reduction was similar with pasireotide and placebo.

    Peptide
    Pasireotide
    Outcome
    No significant changeCyst diameter reduction at 26 weeks
    Study

    n = 34

    Comparator
    Placebo with aspiration sclerotherapy
    Analysis
    Secondary
    Outcome group
    Cyst size · Liver
    Studied dose
    60 mg long-acting release, two injections · intramuscular · Injections 2 weeks before and 2 weeks after aspiration sclerotherapyAs given in this study (human).

    Measurements

    Long-term cyst diameter reduction at 26 weeks
    49.1%
    pasireotide LAR
    Long-term cyst diameter reduction at 26 weeks
    45.6%
    placebo
    IQR, cyst diameter reduction at 26 weeks
    27 to 73.6%
    pasireotide LAR
    IQR, cyst diameter reduction at 26 weeks
    29.6 to 59.6%
    placebo
    P value
    0.9
    pasireotide versus placebo, 26 weeks

    Source sentences

    Summary
    Long-term cyst diameter reduction was similar in both groups (49.1 % [27.0-73.6] and 45.6 % [29.6-59.6]; p = 0.90).
    4 context sentences
    Summary · context
    Secondary outcomes included long-term cyst reduction at 26 weeks, patient-reported outcomes including the polycystic liver disease-questionnaire (PLD-Q) and safety.
    Summary · context
    We conducted a double-blind, placebo-controlled trial in patients who underwent aspiration sclerotherapy of a large (>5 cm) symptomatic hepatic cyst.
    Summary · context
    Patients were randomized to either intramuscular injections of pasireotide 60 mg long-acting release (n = 17) or placebo (sodium chloride 0.9 %, n = 17).
    Summary · context
    Injections were administered 2 weeks before and 2 weeks after aspiration sclerotherapy.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In hepatic cyst patients undergoing aspiration sclerotherapy, mean PLD-Q scores improved significantly in both groups (p<0.01), with no difference between pasireotide and placebo arms (p=0.92).

    In plain wordsIn hepatic cyst patients, questionnaire scores improved in both groups, including placebo, and did not differ between pasireotide and placebo.

    Peptide
    Pasireotide
    Outcome
    No significant changePLD-Q score between arms
    Study

    n = 34

    Comparator
    Placebo with aspiration sclerotherapy
    Analysis
    Secondary
    Outcome group
    Quality of life · Liver
    Studied dose
    60 mg long-acting release, two injections · intramuscular · Injections 2 weeks before and 2 weeks after aspiration sclerotherapyAs given in this study (human).

    Measurements

    P value, PLD-Q improvement within groups
    < 0.01
    both groups
    P value, PLD-Q between arms
    0.92
    pasireotide versus placebo

    Source sentences

    Summary
    Mean PLD-Q scores improved significantly in both groups (p < 0.01) without differences between arms (p = 0.92).
    3 context sentences
    Summary · context
    We conducted a double-blind, placebo-controlled trial in patients who underwent aspiration sclerotherapy of a large (>5 cm) symptomatic hepatic cyst.
    Summary · context
    Patients were randomized to either intramuscular injections of pasireotide 60 mg long-acting release (n = 17) or placebo (sodium chloride 0.9 %, n = 17).
    Summary · context
    Injections were administered 2 weeks before and 2 weeks after aspiration sclerotherapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.